4DIXON R, HOWES J, GENTILE J, et al. Nalmefene: intravenous safety and kinetics of a new opioid antagonists [J]. Clin Pharmacol Ther,1986, 39(1): 49-53.
7HANG CS, IMAI N, STONE CK, et al. The role of endogenous opioids in congestive heart failure: effects of nalmefene on systemic and regional hemodynamics in dog[J]. Circulation, 1987, 75(2): 443-451.
8LUTSEP HL, ELARK WM. Neuroprotection in acute ischemic stroke: current status and future potential [J]. Drugs,1999, 1(1):3-8.
9WALKER BM, KOOB GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence[J].Neuropsychopharmacyology,2007,2:156-157.
10ACETO MD, HARRIS LS, MAY EL. Dependence studies of new compounds in the rhesus monkey, rat, and mouse (1985)[J]. NIDA Res Monogr, 1986, 67:399-452.
3Angus DC,Linde-Zwirble WT,Lidicker J,et al.Epidemiology of severe sepsis in the United States:analysis of incidence,outcome,and associated costs of care.Crit Care Med,2001,29:1303-1310.
5Koyama S,Santiesteban HL,Ammons WS,et al.The effects of naloxone on the peripheral sympathetics in cat endotoxin shock.Circ Shock,1983,10:7-13.
6Michel ME,Bolger G,Weissman BA.Binding of a new opiate antagonist,nalmefene,to rat brain membranes.Methods Find Exp Clin Pharmacol,1985,7:175-177.
7Liang CS,Imai N,Stone CK,et al.The role of endogenous opioids in congestive heart failure:effects of nalmefene on systemic and regional hemodynamics in dogs.Circulation,1987,75:443-451.
8Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference.Intensive Care Med,2003,29:530-538.
9Dellinger RP,Levy MM,Carlet JM,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock:2008.Crit Care Med,2008,36:296-327.
10Weissglas IS.The role of endogenous opiates in shock:experimental and clinical studies in vitro and in vivo.Adv ShockRes,1983,10:87-94.
